Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos NV (NASDAQ:GLPG) stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing.
Galapagos NV（納斯達克股票代碼：GLPG）的股票在週一交易中上漲，因爲Ecor1 Capital在一份13D備案中報告了對這家歐洲生物技術公司的9.9%持股。
EcoR1 Capital is now planning to talk to the Belgian biotech about its performance, business, operations, strategic opportunities, and governance, including Board composition.
EcoR1 Capital現在計劃就比利時生物技術公司的業績、業務、運營、戰略機遇和治理進行溝通，包括董事會組成。
By June 2023, the biotech-focused investment fund had accumulated a 9.87% stake in the company.
到2023年6月，這家專注於生物技術的投資基金已經積累了該公司9.87%的股權。
Also Read: Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst.
另請閱讀：Galapagos遭下調評級，製藥公司面臨緩慢的研發進展之路：分析師。
The SEC filing provides details of how EcoR1 views Galapagos and how it plans to use its stake to try to shape the direction of the biotech, with the investor stating that the company's shares are "deeply undervalued and represent an attractive investment opportunity."
SEC的備案提供了EcoR1對Galapagos的看法，並展示了它計劃如何利用其股權來塑造公司的發展方向。該投資者稱該公司的股票「被嚴重低估，並代表了一個有吸引力的投資機會。」
Galapagos' share price has fallen more than 25% over the past year, but the stock has performed even worse over a longer period.
在過去的一年裏，Galapagos的股價下跌了超過25%，但在更長的時間裏，該股票的表現更差。
Galapagos, once seen as one of Europe's leading drug innovators, has struggled in recent years due to R&D failures, regulatory challenges, and ineffective partnerships, Stat News noted.
據Stat News報道，Galapagos曾被視爲歐洲領先的藥物創新企業之一，但近年來由於研發失敗、監管挑戰和無效的合作伙伴關係而陷入困境。
In 2022, Paul Stoffels, a renowned drug developer and former Johnson & Johnson executive, returned from a brief retirement to become the company's CEO.
2022年，著名藥物開發者、前強生公司高管保羅·斯托夫爾斯從短暫的退休回歸，成爲該公司的首席執行官。
Stoffels vowed to revamp Galapagos' R&D, focusing on CAR-T cancer therapies, but the report adds that progress has been sluggish and underwhelming in Wall Street's eyes.
Stoffels發誓重組Galapagos的研發部門，專注於CAR-t癌症療法，但報告指出，在華爾街的眼中，進展緩慢且令人失望。
According to data from Benzinga Pro, the company's enterprise value is negative $2.1 billion, indicating that its cash reserves outweigh the value of its assets, including its drug pipeline.
根據Benzinga Pro的數據，該公司的企業價值爲負21億美元，表明其現金儲備超過了其資產價值，包括其藥物管線。
Most recently, the FDA cleared Galapagos' Investigational New Drug application for ATALANTA-1 Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma.
最近，FDA批准了Galapagos的ATALANTA-1第1/2期多中心研究中的新藥申請，該研究評估GLPG5101在復發/難治性非霍奇金淋巴瘤患者中的可行性、安全性和療效。
Price Action: GLPG stock is up 10.4% at $28.59 at last check Monday.
價格走勢：GLPG股價在上週一最後一次查詢時上漲了10.4%，報28.59美元。
Illustration of Phrama lab worker created with MidJourney.
藥廠實驗室工作者插圖，由MidJourney創建。
- Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program.
- 美國人可免費獲得COVID-19檢測套裝，因美國政府重新啓動免費家庭測試計劃。
譯文內容由第三人軟體翻譯。